Jingchun Zhang
St. Paul's Hospital
Vancouver, BC, Canada
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Developing a Personalized Cancer Nanovaccine Using Coxsackievirus-Reprogrammed Cancer Cell Membranes for Enhanced Anti-Tumor Immunity.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 16, 2025
Synergistic Viro-chemoimmunotherapy in Breast Cancer Enabled by Bioengineered Immunostimulatory Exosomes and Dual-Targeted Coxsackievirus B3.
Journal: ACS nano
Published: January 26, 2024
Engineering a facile and versatile nanoplatform to facilitate the delivery of multiple agents for targeted breast cancer chemo-immunotherapy.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 15, 2023
A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
Journal: Cancer letters
Published: April 19, 2022
Sublethal enteroviral infection exacerbates disease progression in an ALS mouse model.
Journal: Journal of neuroinflammation
Published: July 26, 2021
FUS/TLS Suppresses Enterovirus Replication and Promotes Antiviral Innate Immune Responses.
Journal: Journal of virology
Published: March 11, 2021
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma.
Journal: Molecular therapy oncolytics
Published: February 10, 2019
Enteroviral Infection Leads to Transactive Response DNA-Binding Protein 43 Pathology in Vivo.
Journal: The American journal of pathology
Published: March 07, 2018
Cleavage of Grb2-Associated Binding Protein 2 by Viral Proteinase 2A during Coxsackievirus Infection.
Journal: Frontiers in cellular and infection microbiology
Published: December 18, 2016
Dysferlin deficiency confers increased susceptibility to coxsackievirus-induced cardiomyopathy.
Journal: Cellular microbiology
Published: January 30, 2015
Last Updated: 09/26/2026